FDA Grants Priority Review to Frontline Cabozantinib in RCC

October 16, 2017 – The FDA has granted a priority review to a supplemental new drug application (sNDA) for cabozantinib for previously untreated patients with advanced renal cell carcinoma (RCC), according to Exelixis, the developer of the multikinase inhibitor. The sNDA is based on the phase II CABOSUN trial, in which cabozantinib reduced the risk of progression or death by 34% versus sunitinib as a first-line treatment for patients with metastatic RCC. The … (leggi tutto)